(PDF) P2.04-12 a Genomic Signature [JAK2, JAK3, PIAS4,

P2.04-12 a Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1236

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.04-11 an IL-8/IFN-gammma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients With NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-20 Advanced NSCLC Treatment and Outcomes After Nivolumab

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated With Nivolumab

Journal of Thoracic Oncology

Respiratory Medicine

English

A Panel of 12-lncRNA Signature Predicts Survival of Pancreatic Adenocarcinoma

Journal of Cancer

English

MA11.03 Interaction of Tumor Infiltrating Lymphocytes and Cancer Nuclei Predicts Response to Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

P023 Factors Associated With Administration of Subsequent Cytotoxic Chemotherapy After Nivolumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-84 High Basal Serum EGF Levels Predicts Response to CIMAvax-EGF, a Therapeutic Vaccine for Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English